Kalkine has a fully transformed New Avatar.

KALIN®

Kalkine Daily 16/06/2015 + Ramsay Healthcare

Jun 19, 2015

In today’s daily we have covered stock research on Ramsay Healthcare (Expensive).









 

The S&P 500 was down by 9.68 points or 0.46% to 2084.43 on Monday. Stocks fell on Wall Street on Monday as investors fretted over the consequences of a possible debt default by Greece, but talk of multi-billion dollar healthcare deals buoyed shares in the sector, cutting into the market's loss. After Sunday's breakdown of the cash-for-reform talks between Athens and its creditors, Greece has two weeks before facing a 1.6 billion euro repayment due to the International Monetary Fund that could leave it out of cash. On Monday, positions among negotiators hardened.

Cigna shares jumped as much as 19.4 percent to a record high of $164, buoying the health sector, after the Wall Street Journal reported Cigna rebuffed a takeover offer from rival AnthemInc that valued it at about $45 billion. Cigna closed up 11.7 percent to $153.43. Shares of United Technologies weighed the most on the Dow Industrials, down 2.5 percent at $114.61. It said it is exiting the helicopter business and would decide whether to spin off or sell its $8 billion Sikorsky unit, the U.S. military's largest helicopter maker.


 



United Technologies Daily Chart (Source - Thomson Reuters)
 

S&P ASX 200 was down by 6.50 points or 0.12% on Monday and closed at 5538.80 points.Woodside Petroleum led the downward slide, shedding 2.9 per cent to close on $35.67, followed by Telstra, down 0.7 per cent to $5.99, and also Newcrest Mining Group, down 3.3 per cent to $13.09. The Commonwealth Bank closed 0.6 per cent up to $81.89; Westpac BankingCorporation finished up 0.2 per cent at $31.72; the National Australia Bank fared marginally better, up 0.8 per cent to $31.72, while ANZ Banking Group rose 0.4 per cent to $31.85.

Mining stocks were also patchy, with Rio Tinto up 0.3 per cent to close at $57.29, and BHP Billiton closed at $27.92, less than 0.1 per cent lower. Arrium was one of the biggest losers of the day, dropping 6.3 per cent to 15c. STW Communications Group grew 7.4 per cent to $0.65, while Metcash made back a little ground after weeks of decline, adding 2.2 per cent to close on $1.13. The Australian dollar is trading at US77.63¢, compared with Monday's local close of US77.32¢. SPI futures are down 11 points.
 




Woodside Petroleum Daily Chart (Source - Thomson Reuters)



Top Performers ASX 200 :-



 



 


 

Get up to 2 Years of free subscription by inviting your friends to KALKINE!

For every friend of yours who joins KALKINE, we'll give you 3 months of free subscription (up to a limit of 24 months free subscription). If you recommend 3 friends and they join within a month of you referring them, you get 1 year free subscription to KALKINE reports added to your account (up to a limit of 24 months free subscription). Simply reply to this email with their name, e-mail and phone number.
 






 

Stock Of The Day - Ramsay Healthcare (Expensive)

In today’s daily we cover Ramsay Health Care Limited (RHC).  The company recently made a presentation on UBS healthcare forum, whose main highlights were a growth plan to achieve a core NPAT and core EPS growth of 18% to 20% for full year FY2015. 


Demand for Healthcare (Source - Company Reports)

The main basis for this growth, are cited to be strong industry fundamentals. Demand for healthcare care will remain strong for an ageing population, with longer life expectancy, increase in chronic disease burden, population growth and improvement in treatment and diagnostic measures. The global population aged 60 or above is expected to more than triple by 2050. The current growth rate is of older population at 1.9% and is significantly higher than that of total population at 1.2%. The population is Australia will grow from 23.9 million to 39.7 million at an average growth rate of 1.3% per annum by 2054. The UK Population is predicted to increase by 9.6 million (15%) to 73.3 million over the 25 years period to mid 2037. New Technologies and innovations will continue to drive the demand of healthcare in these countries. The increased prevalence of chronic health diseases will also increase the demand of treatment. 


Dividend Growth (Source - Company Reports)

The company has a strong trend of growth in the past few years. Revenue growth has been achieved by a combination of organic growth, brownfield capacity expansion and acquisitions. The organic growth of the company has been achieved by the demographics, quality portfolio of hospitals and ongoing business improvement. The company has been continuously targeting to meet unmet demands by driving Ramsay’s ongoing investment in capacity expansion.


Revenue Growth Milestones (Source - Company Reports)

There is a potential for more partnerships to manage or develop to provide more hospital services in the changing political landscape. The company is further exploring acquisitions in existing and other markets. The company has proven that it can export it’s management model which it claims is the main reason for increase in shareholder value. The operating revenue of the company has grown at a compounded annual growth rate of 21.7% for the 17 years from FY1997 to FY 2014. Apart from growth in operating revenues the company has also registered growth in the core EPS and dividends with dividend growth at a compounded annual growth rate of 16.5% for the 17 years from FY1997 to FY 2014 and EPS growth at a compounded annual growth rate of 16.6% for the 17 years from FY1997 to FY 2014. Dividends have grown in line with EPS due to the company’s policy of maintenance of a full year dividend payout ration of 50%. The company has approved over $1.5 billion worth of Brownfield capacity over the last 9 years. Brownfield capacity expansion opportunities identified at least of $1 billion in the next five years.  


Growth Opportunities (Source - Company Reports)

For the six months period ending 31 December 2014, company increased its NPAT by 19.1% to $204 million and the core EPS was up 20.2% to 97.6 cents. The group revenue increased by 41.6% to $3.3 billion, while EBIT was up by 32.2% to $377.8 billion. The group leverage ratio has decrease from 5.1 to 2.6 over the years signifying an increasingly healthy balance sheet.


RHC Daily Chart (Source - Thomson Reuters)

The EBITDA of Australian hospitals increased from 18.8% to 19.3% for the six months period ending 31 December 2014. Private health insurance in Australia remains strong at 47.2% participation. The company completed $175 million of Brownfields in the first year and further brownfield opportunities have been identified for the next six months. The growth numbers are backed by strong growth in admissions indicating that the majority of the growth is still organic. The EBITDA of the UK business increased as well rising 8.3% for the six months period ending 31 December 2014. There can be further improvement since UK PMI is showing signs of recovery. There was a strong double-digit growth in NHS admissions of 12% in the first half. The EBITDA of the French operations grew by 582% for the six months period ending 31 December 2014, as a combination of organic growth and acquisitions. The company is also laying down the groundwork for growth in Asia. 
 

The company is currently trading at a stock price of $60.960, which is somewhere close to the 52 week high of 69.220 and further from the 52 week low of 43.760. At the current price the company is trading at a Price to Earnings multiple of 36.8 and a dividend yield of 1.574%. Most of the companies in the sector are trading at a lesser P/E ratio. The stock can be thus considered expensive as compared to its peers. 

While the company has a long positive trend of growth over a period of time, much of that growth is already factored in the high P/E ratio of the stock. Most of the growth plans of the company are based on the improvement of sector fundamentals, which will also benefit other players in the sector which are selling at a lesser P/E multiple. Given the relative overvaluation in the sector, we believe that the stock is expensive at the current price of $61.40.



 


Level 13  167 Macquarie Street
Sydney NSW 2000 Australia
E-Mail - [email protected]
Phone - 02 8667 3147


        
Note - You can also view this daily in the special reports section.

 


Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.
Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).
The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.
Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.
The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide.